Task force report on the management of thrombosis in antiphospholipid syndrome

Abstract

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies (aPL): lupus anticoagulant test, anticardiolipin antibodies, and/or anti ß2 glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is subject of controversy. In the setting of the 13th International Congress on Antiphospholipid Antibodies, held in Galveston in April 2010, an international Task Force composed of clinicians and researchers with experience in the field jointly elaborated a consensus document on the primary and secondary thromboprophylaxis in individuals with aPL.